Cowen Remains Bullish on Acorda Therapeutics (ACOR) Following Announced Settlement with Allergan's Actavis

Cowen reiterated an Outperform rating and $65.00 price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) following the announced settlement with Allergan's Actavis over generic Ampyra. Under the terms of the agreement, Actavis will be allowed to market generic Ampyra in 2027.

Analyst Phil Nadeau commented, "This morning Acorda announced a settlement with Actavis over generic Ampyra. Actavis will be allowed to launch a generic in 2027. We think this is a positive development as the settlement terms are favorable, it sets a good precedent for future settlements, and is a necessary step toward maintaining Ampyra's exclusivity. We continue to think that ACOR is undervalued."

For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.

Shares of Acorda Therapeutics, Inc. closed at $28.05 yesterday.

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on Edwards Lifesciences (EW)
• Faraday Technology Corp (3035:TT) PT Lowered to NT$378 at Jefferies
• Stifel: Instacart (CART) Under Pressure After Amazon (AMZN) Announces Unlimited Grocery Delivery Subscription